JP2005517412A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005517412A5 JP2005517412A5 JP2003568094A JP2003568094A JP2005517412A5 JP 2005517412 A5 JP2005517412 A5 JP 2005517412A5 JP 2003568094 A JP2003568094 A JP 2003568094A JP 2003568094 A JP2003568094 A JP 2003568094A JP 2005517412 A5 JP2005517412 A5 JP 2005517412A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antisense oligonucleotide
- nephropathy
- activity
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35637402P | 2002-02-12 | 2002-02-12 | |
| PCT/US2003/004186 WO2003068983A1 (en) | 2002-02-12 | 2003-02-12 | Use of the axl receptor for diagnosis and treatment of renal disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005517412A JP2005517412A (ja) | 2005-06-16 |
| JP2005517412A5 true JP2005517412A5 (https=) | 2006-04-13 |
Family
ID=27734638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003568094A Pending JP2005517412A (ja) | 2002-02-12 | 2003-02-12 | 腎疾患の診断及び治療のためのＡｘｌ受容体の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20030157573A1 (https=) |
| EP (1) | EP1483400A4 (https=) |
| JP (1) | JP2005517412A (https=) |
| CN (1) | CN1646695A (https=) |
| AU (1) | AU2003223172A1 (https=) |
| IL (1) | IL163547A0 (https=) |
| WO (1) | WO2003068983A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL163547A0 (en) * | 2002-02-12 | 2005-12-18 | Quark Biotech Inc | Use of the axl receptor for diagnosis and treatment of renal disease |
| US8574827B2 (en) * | 2002-10-29 | 2013-11-05 | Rigel Pharmaceuticals, Inc. | Modulators of angiogenesis and tumorigenesis |
| WO2005102456A1 (en) | 2004-03-27 | 2005-11-03 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Composition and method for cancer treatment |
| TW200726845A (en) * | 2006-01-02 | 2007-07-16 | Nat Defense Medical Ct | Biomarker molecular of renal illness and detecting method for the same |
| JP2010514810A (ja) | 2006-12-29 | 2010-05-06 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ａｘｌインヒビターとして有用な置換トリアゾール |
| CA2692320A1 (en) * | 2007-07-02 | 2009-01-08 | Wyeth | Methods of treating bone disorders with modulators of axl |
| US9074192B2 (en) | 2010-01-22 | 2015-07-07 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL signaling in anti-metastatic therapy |
| PT2525824T (pt) | 2010-01-22 | 2017-07-13 | Univ Leland Stanford Junior | Inibição da sinalização de axl em terapêutica antimetastática |
| US9879061B2 (en) | 2011-12-15 | 2018-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis |
| DK2810937T3 (en) | 2012-01-31 | 2017-03-13 | Daiichi Sankyo Co Ltd | PYRIDONE DERIVATIVES |
| EP2626705A1 (en) * | 2012-02-13 | 2013-08-14 | Institut d'Investigacions Biomédiques August Pi i Sunyer | Use of the soluble form of AXL in the diagnosis and/or prognosis of heart failure syndrome |
| EP3076966A2 (en) * | 2013-12-02 | 2016-10-12 | BerGenBio AS | Use of kinase inhibitors |
| CN107003301B (zh) | 2014-10-20 | 2019-11-01 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
| US10137173B2 (en) | 2014-10-20 | 2018-11-27 | Aravive Biologics, Inc. | Antiviral activity of Gas6 inhibitor |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| JP2020504157A (ja) | 2017-01-12 | 2020-02-06 | アスチュート メディカル，インコーポレイテッド | Ｃ−ｃモチーフケモカインリガンド１４の測定に基づく腎損傷および腎不全の評価および処置のための方法および組成物 |
| WO2018193102A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| CN113215157B (zh) * | 2021-05-20 | 2022-06-21 | 徐州医科大学 | 特异性靶向人AXL基因的sgRNA及其应用 |
| CN113252911B (zh) * | 2021-07-02 | 2021-12-10 | 珠海丽珠试剂股份有限公司 | SARS-CoV-2中和抗体的检测试剂盒及其应用 |
| KR102763266B1 (ko) * | 2021-11-30 | 2025-02-04 | 충남대학교산학협력단 | Axl을 포함하는 지방간 예방 또는 치료용 조성물 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5468634A (en) * | 1991-06-24 | 1995-11-21 | The University Of North Carolina At Chapel Hill | Axl oncogene |
| CA2175893C (en) * | 1993-11-23 | 2010-06-22 | Paul J. Godowski | Protein tyrosine kinases named rse |
| WO1995019570A1 (en) * | 1994-01-14 | 1995-07-20 | Genentech, Inc. | Antagonists to insulin receptor tyrosine kinase inhibitor |
| US5538861A (en) * | 1994-07-29 | 1996-07-23 | Amgen Inc. | DNA encoding a stimulating factor for the axl receptor |
| US6211142B1 (en) * | 1995-03-10 | 2001-04-03 | Genentech, Inc. | Compositions comprising gas6 polypeptides and articles of manufacture comprising the same |
| US5849585A (en) * | 1995-05-10 | 1998-12-15 | Genetech, Inc. | Isolating and culturing Schwann cells |
| US20040102389A1 (en) * | 1995-10-26 | 2004-05-27 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
| US6235769B1 (en) * | 1997-07-03 | 2001-05-22 | Sugen, Inc. | Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase |
| US6236769B1 (en) * | 1998-01-28 | 2001-05-22 | Cognex Corporation | Machine vision systems and methods for morphological transformation of an image with zero or other uniform offsets |
| US20030149113A1 (en) * | 2001-10-12 | 2003-08-07 | Caplan Michael J. | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease |
| CA2429814C (en) * | 2000-12-01 | 2014-02-18 | Thomas Tuschl | Rna interference mediating small rna molecules |
| US20020165158A1 (en) * | 2001-03-27 | 2002-11-07 | King George L. | Methods of modulating angiogenesis |
| US20030157030A1 (en) * | 2001-11-02 | 2003-08-21 | Insert Therapeutics, Inc. | Methods and compositions for therapeutic use of rna interference |
| IL163547A0 (en) * | 2002-02-12 | 2005-12-18 | Quark Biotech Inc | Use of the axl receptor for diagnosis and treatment of renal disease |
| US20030229906A1 (en) * | 2002-04-15 | 2003-12-11 | Gelman Irwin H. | Methods and compositions for the treatment of disorders of HIV infection |
| JP2007524349A (ja) * | 2003-01-16 | 2007-08-30 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | ＩＣＡＭ−１のｓｉＲＮＡ阻害のための組成物及び方法 |
-
2003
- 2003-02-12 IL IL16354703A patent/IL163547A0/xx unknown
- 2003-02-12 JP JP2003568094A patent/JP2005517412A/ja active Pending
- 2003-02-12 AU AU2003223172A patent/AU2003223172A1/en not_active Abandoned
- 2003-02-12 EP EP03719300A patent/EP1483400A4/en not_active Withdrawn
- 2003-02-12 WO PCT/US2003/004186 patent/WO2003068983A1/en not_active Ceased
- 2003-02-12 US US10/365,135 patent/US20030157573A1/en not_active Abandoned
- 2003-02-12 CN CNA038082365A patent/CN1646695A/zh active Pending
-
2007
- 2007-07-10 US US11/827,198 patent/US20090075923A1/en not_active Abandoned
-
2008
- 2008-01-07 US US12/006,999 patent/US20090042826A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005517412A5 (https=) | ||
| JP2023058575A5 (https=) | ||
| JP2014511686A5 (https=) | ||
| JP2006500958A5 (https=) | ||
| JP2020058368A5 (https=) | ||
| JP2017536119A5 (https=) | ||
| JP2013535212A5 (https=) | ||
| JP2012050438A5 (https=) | ||
| JP2012029693A5 (https=) | ||
| JP2023519140A5 (https=) | ||
| JP2010533171A5 (https=) | ||
| JP2020022483A5 (https=) | ||
| JP2009506124A5 (https=) | ||
| EP1723162A4 (en) | ANTI-microRNA oligonucleotide molecules | |
| JP2005517430A5 (https=) | ||
| JP2005517452A5 (https=) | ||
| WO2007134014A3 (en) | Compounds and methods for modulating expression of gcgr | |
| JP2008513513A5 (https=) | ||
| JP2009544281A5 (https=) | ||
| EP2062586A3 (en) | Use of low doses of oligonucleotides antisense to tgf-beta, vegf, interleukin-10, c-jun, c-fos or prostaglandin e2 genes in the treatment of tumors | |
| JP2006502243A5 (https=) | ||
| JP2013537404A5 (https=) | ||
| JP2003219893A5 (https=) | ||
| JP2022537987A5 (https=) | ||
| JP2007517498A5 (https=) |